[P1–401]: Association Between Adherence of Alzheimer's Disease Medication and 3d‐ssp Decrease Images

Araki, Yuzo; Huruichi, Masahiro; Nokura, Hiroaki

doi:10.1016/j.jalz.2017.06.417

Cited by 1 publication

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies suggest that the perfusion increase after AChEI treatment is only temporary [18,30,40]. More specifically, an increase in perfusion and cognitive functioning was reported after six months of treatment, which disappeared again after eighteen months.…”

Section: Discussionmentioning

confidence: 99%

“…the temporal lobe perfusion [20, 24-26, 29, 31, 38, 40, 41], while half of the studies reported no perfusion changes (52%) [18,19,22,23,27,28,30,[32][33][34][35][36][37]. Only three studies (12%) reported a perfusion decrease in the temporal cortex [21,35,37].…”

Section: Temporal Cortexmentioning

confidence: 99%

Section: Treatment Durationmentioning

confidence: 99%

“…The influence of treatment duration on cerebral perfusion changes was evaluated in patients with AD at baseline, after short-term (3-6 months) and long-term treatment (12-18 months) in three studies (Table 3) [18,30,40,42]). At baseline, the patients showed a global perfusion decrease compared to healthy individuals [18]. After 3-6 months of treatment, either no perfusion changes were observed [18,30] or either an increase in cerebral perfusion was reported, mainly in the frontal [40], temporal [40], and parietal lobe [40], as well as the PCC [30].…”

Section: Treatment Durationmentioning

confidence: 99%

“…When assessing acute effects, the impact of physostigmine on cerebral perfusion was investigated, 10 min to 2 h after treatment (average follow-up (FU): 32 min) [15][16][17]. The chronic effects of donepezil (n reports = 20) [18][19][20][21][22][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42], rivastigmine (n reports = 6) [19,21,[24][25][26][27], and galantamine (n reports = 6) [18][19][20][21][22][23], were investigated with an average waiting time of 8.7 months (ranging between three and 18 months). 21 studies [18, 20, 21, 23-36, 38, 40-42] investigated and compared the cerebral perfusion effects of a single drug, whereas 4 studies [19][20][21][22] compared the effects of different AChEIs by using multiple treatment groups.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review

Moyaert,

Beun,

Achten

et al. 2023

JAD

View full text Add to dashboard Cite

Background: Perfusion imaging has the potential to identify neurodegenerative disorders in a preclinical stage. However, to correctly interpret perfusion-derived parameters, the impact of perfusion modifiers should be evaluated. Objective: In this systematic review, the impact of acute and chronic intake of four acetylcholinesterase inhibitors (AChEIs) on cerebral perfusion in adults was investigated: physostigmine, donepezil, galantamine, and rivastigmine. Results: Chronic AChEI treatment results in an increase of cerebral perfusion in treatment-responsive patients with Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease dementia in the frontal, parietal, temporal, and occipital lobes, as well as the cingulate gyrus. These effects appear to be temporary, dose-related, and consistent across populations and different AChEI types. On the contrary, further perfusion decline was reported in patients not receiving AChEIs or not responding to the treatment. Conclusion: AChEIs appear to be a potential perfusion modifier in neurodegenerative patients. More research focused on quantitative perfusion in both patients with and without a cholinergic deficit is needed to draw conclusions on whether AChEI intake should be considered when analyzing perfusion data.

show abstract

Section: Discussionmentioning

confidence: 99%